Brian C. Stephenson - Dec 3, 2021 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role
Title: Secretary, Treasurer and Chief Financial Officer
Signature
Yi Ching Yau, Attorney-in-Fact
Stock symbol
BBIO
Transactions as of
Dec 3, 2021
Transactions value $
$0
Form type
4
Date filed
12/7/2021, 05:05 PM
Previous filing
Nov 18, 2021
Next filing
Feb 18, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BBIO Stock Option (right to buy) Award $0 +211K $0.00 211K Dec 3, 2021 Common Stock 211K $38.62 Direct F1
transaction BBIO Restricted Stock Units Award $0 +15.1K $0.00 15.1K Dec 3, 2021 Common Stock 15.1K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests and becomes exercisable as to 25% of the underlying shares on December 3, 2022 and thereafter in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.
F2 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F3 The RSUs will vest with respect to 25% of the underlying shares on November 16, 2022. Thereafter, 1/12th of the remaining underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on November 16, 2025, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.

Remarks:

Title: Secretary, Treasurer and Chief Financial Officer